AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/10/20

Aerie Pharmaceuticals (NASDAQ: AERI ) initiated with Neutral rating and $27 (6% upside) price target at Bank of America. More news on: Aurinia Pharmaceuticals Inc., BeyondSpring Inc., Cerecor Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...

Those who are new to investing may not understand what penny stocks are. You will typically find penny stocks on over-the-counter markets. According to the SEC, the definition of a penny stock is any equity that trades below $5. You will soon learn that this pricing is justified in a few mom...

As one of the largest pharma companies out there, I suppose it stands to reason that Roche ( OTCQX:RHHBY ) would have an above-average level of newsflow, but tracking the developments at Roche over the last couple of months has been like trying to sip from a firehose. It’s well worth ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public ...

Buyout mania has definitely taken over the biopharma industry  lately. With the year winding down, we've witnessed numerous transactions in the space at absolutely gobsmacking premiums. Here is a brief overview of the biggest deals over the past two months. Best of all, this trend should ...

December 11, 2019 Palm Beach, FL –December 11, 2019 – For the last half century, if not more, doctors have been working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor...

After reporting favorable pricing for its previously disclosed equity offering, shares in Aurinia Pharmaceuticals (NASDAQ: AUPH) rallied 12.2% on Tuesday. It's been a busy week for Aurinia's investor relations team. On Dec. 4, the company reported positive phase 3 trial results for ...

Gainers:  Technical Communications (NASDAQ: TCCO ) +323% . More news on: Technical Communications Corporation, Venus Concept Inc., Iterum Therapeutics plc, Stocks on the move, Read more ...

Aurinia Pharmaceuticals (NASDAQ: AUPH ) prices public offering of 11.12M common shares at $15/share for gross proceeds of $166.7M. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Read more ...